WO2019161211A3 - Compositions and methods for the reduction or prevention of hepatic steatosis and nash - Google Patents

Compositions and methods for the reduction or prevention of hepatic steatosis and nash Download PDF

Info

Publication number
WO2019161211A3
WO2019161211A3 PCT/US2019/018230 US2019018230W WO2019161211A3 WO 2019161211 A3 WO2019161211 A3 WO 2019161211A3 US 2019018230 W US2019018230 W US 2019018230W WO 2019161211 A3 WO2019161211 A3 WO 2019161211A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
nash
compositions
hepatic steatosis
prevention
Prior art date
Application number
PCT/US2019/018230
Other languages
French (fr)
Other versions
WO2019161211A2 (en
Inventor
Michael ZEMEL
Antje BRUCKBAUER
Jheelam BANERJEE
Original Assignee
Nusirt Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nusirt Sciences, Inc. filed Critical Nusirt Sciences, Inc.
Publication of WO2019161211A2 publication Critical patent/WO2019161211A2/en
Publication of WO2019161211A3 publication Critical patent/WO2019161211A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Methods useful for reducing or preventing hepatic steatosis and NASH are provided herein. Such methods may comprise administering to a subject in need thereof an FXR agonist in combination with an amount of a branched amino acid in free amino acid form, such as leucine, or a metabolite thereof. Also provided herein are compositions and kits for practicing any of the methods described herein.
PCT/US2019/018230 2018-02-15 2019-02-15 Compositions and methods for the reduction or prevention of hepatic steatosis and nash WO2019161211A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862631164P 2018-02-15 2018-02-15
US62/631,164 2018-02-15

Publications (2)

Publication Number Publication Date
WO2019161211A2 WO2019161211A2 (en) 2019-08-22
WO2019161211A3 true WO2019161211A3 (en) 2020-04-30

Family

ID=67619037

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2019/018230 WO2019161211A2 (en) 2018-02-15 2019-02-15 Compositions and methods for the reduction or prevention of hepatic steatosis and nash

Country Status (1)

Country Link
WO (1) WO2019161211A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117398391A (en) * 2022-07-14 2024-01-16 爱医谷(苏州)生物科技有限公司 Composition for resisting aging and application or method thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050158408A1 (en) * 1998-07-24 2005-07-21 Yoo Seo H. Dried forms of aqueous solubilized bile acid dosage formulation: preparation and uses thereof
US20160213639A1 (en) * 2013-10-07 2016-07-28 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050158408A1 (en) * 1998-07-24 2005-07-21 Yoo Seo H. Dried forms of aqueous solubilized bile acid dosage formulation: preparation and uses thereof
US20160213639A1 (en) * 2013-10-07 2016-07-28 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis

Also Published As

Publication number Publication date
WO2019161211A2 (en) 2019-08-22

Similar Documents

Publication Publication Date Title
PH12016501668A1 (en) Compositions and methods for the reduction or prevention of hepatic steatosis
WO2021217004A3 (en) Methods and compositions for treating virus-associated inflammation
PH12018501956A1 (en) 3-desoxy derivative and pharmaceutical compositions thereof
EP4234030A3 (en) Pd-1/pd-l1 inhibitors
WO2017040407A8 (en) Compositions and methods for the reduction or prevention of non-alcoholic steatohepatitis (nash)
EP3820885A4 (en) Methods and compositions for delivery of agents across the blood-brain barrier
WO2019120234A3 (en) Compound functioning as bromodomain protein inhibitor, and composition
WO2018224689A3 (en) Solid compositions for oral administration
EP4299133A3 (en) Compositions and methods for the delivery of therapeutics
MX2019000795A (en) Liquid cleansing compositions with an antibacterial system and method of manufacturing thereof.
MX360111B (en) Conveyor lubricants including emulsions and methods employing them.
WO2018144460A8 (en) Topcoat for permanent lip make up
MX2016013575A (en) Composition for preventing or treating fatty liver diseases.
WO2018094265A3 (en) Method of treating glycogen storage disease
MX2021005120A (en) Aerosolised formulation.
EP3760195A4 (en) Composition comprisng 2,3-butanediol as active ingredient
EP3760626A4 (en) Novel compound and composition for preventing, ameliorating, or treating fibrosis or nonalcoholic steatohepatitis comprising same as active ingredient
EA201890075A1 (en) INJECTABLE PHARMACEUTICAL COMPOSITIONS LEFAMULIN
MX2017010666A (en) (2r,4r)-5-(5'-chloro-2'-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-met hyloxazole-2-carbonyl)amino]pentanoic acid.
WO2016140910A3 (en) Compositions and methods of using anti-mullerian hormone for treatment of infertility
WO2019161211A3 (en) Compositions and methods for the reduction or prevention of hepatic steatosis and nash
MY188643A (en) Cosmetic
AR058621A1 (en) METHODS TO REDUCE REACTIVE PROTEIN C
WO2016149382A3 (en) Compositions and methods for suppressing or reducing systemic immune response in a subject
EP3774708A4 (en) Foxm1 inhibitor compositions and methods of using the same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19753762

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19753762

Country of ref document: EP

Kind code of ref document: A2